Aripiprazole Tablet
Product Images NDC 50268-088

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50268-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-6 (Figure 6)

FDA Label Image

Figure1 (Figure1)

This is a table showing the effect of various drugs on Aripiprazole, with the Aripiprazole fold change and 90% C1. The interacting drugs include a CYP3A4 Inhibitor, CYP2D6 Inhibitor, CYP3A Inducer, Gastric Acid Blockers, valproate, lithium, and lorazepam. The table also shows the relative change of Aripiprazole with each drug, as compared to the reference without the interacting drug.*

FDA Label Image

Figure2 (Figure2)

This text provides information on the effect of different drugs on Aripiprazole. It shows the drugs that inhibit CYP3A4 and CYP2D6 such as ketoconazole and quinidine respectively, and also illustrates the drugs that induce CYP3A4 like carbamazepine. Besides, it covers gastric acid blockers including famotidine and other drugs like valproate and lorazepam. The text also provides a visual representation of the fold change in Dehydro-Aripiprazole and 90% confidence interval in the presence of interacting drugs.*

FDA Label Image

Figure3 (Figure3)

The text provided seems to be a table or figure showing the effect of Aripiprazole on other drugs. The drugs listed are cveas P, Sohpuelon, cvpacs, vartan St g, Ruarian AC, Py, amotigne e, Other e, aproste HE, itim RS, lorazepam HE, wnkhoine, eritzine, and O desmethylamin. The table or figure shows fold change and 50% confidence interval. Without more context or information, it is difficult to provide a more detailed description.*

FDA Label Image

Figure4 (Figure4)

This is a pharmacokinetic study looking at the effect of special populations, such as poor vs. extensive metabolizers, gender, age, and hepatic or renal impairment, on the maximum concentration and area under the curve of avripiprazole. The graph shows the fold change and percentage change relative to the reference. However, some information is missing or not available.*

FDA Label Image

Figure5 (Figure5)

This appears to be pharmacology data comparing the effects of different metabolizer types, gender, age, and liver and kidney function on the pharmacokinetics of a drug. The drug in question is not specified. The data includes changes in AUC and maximum concentration (Cmax) of the drug in relation to these different factors. The last part of the text shows a graph depicting fold changes in Dehydro-Aripiprazole with a confidence interval.*

FDA Label Image

Formula (Screen Shot 2016 04 28 At 11.33.28 Am)

FDA Label Image

2mg Label (Screen Shot 2016 04 29 At 12.00.43 Pm)

This appears to be a partial label of the medication Aripiprazole Tablets, with some information on dosage and product identification. However, there is not enough information to provide a comprehensive description.*

FDA Label Image

5mg Label (Screen Shot 2016 04 29 At 12.01.00 Pm)

FDA Label Image

10mg Label (Screen Shot 2016 04 29 At 12.01.16 Pm)

This is a medication called Aripiprazole which comes in tablet form. There appears to be some product numbers and codes on the packaging, but the text is unclear and not legible. It is likely some information about the medication's dosage and production information.*

FDA Label Image

15mg Label (Screen Shot 2016 04 29 At 12.01.32 Pm)

FDA Label Image

20mg Label (Screen Shot 2016 04 29 At 12.01.50 Pm)

FDA Label Image

30mg Label (Screen Shot 2016 04 29 At 12.02.03 Pm)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.